Heart failure is a clinical syndrome arising when abnormal cardiac structure or function prevents oxygen delivery meeting tissue metabolic demand despite normal filling pressures or only at the expense of elevated filling pressures.
Common predisposing conditions and precipitants of ADHF with associated pathophysiologic mechanisms of impaired CO, findings of key investigations and definitive therapies. ECG, electrocardiogram; echo, echocardiogram; RWMA, regional wall motion abnormality; ACE, angiotensin converting enzyme; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; LVH, LV hypertrophy; LA, left atrium; LAP, left atrial pressure; PAWP, pulmonary artery wedge pressure; RAP, right atrial pressure; PA, pulmonary artery; PAP, PA pressure; PVR, pulmonary vascular resistance; CI, cardiac index; CTPA, computer tomographic pulmonary angiogram. *Details of managing chronic systolic ventricular dysfunction are beyond the scope of this review; however, National Institute of Clinical Excellence, European Society of Cardiology and American Heart Association guidelines should be followed. 1, 2, 6 Predisposing conditions Associated pathophysiology
Key investigations
Definitive treatment of underlying cause
Chronic heart failure with reduced ejection fraction (HFREF) coronary, hypertensive and valvular heart disease; dilated cardiomyopathy; cardiotoxicity (e.g. anthracycline)
#contractility "LAP (neurohumoral activation)
"afterload (ventricular dilatation) ECG-infarction, ischaemia, arrhythmia Echo-EF, dilatation, RWMA, valvulopathy Coronary angiography Exclude haemochromatosis, thyroid disease, thiamine deficiency Endocardial biopsy Goal-directed medical therapy (b-blockade, ACEi, mineralocorticoid receptor antagonist, diuretics)* Revascularization (CABG or PCI) as per major society guidelines 13 Cardiac resynchronization therapy (IA) 2 Surgery: valve repair/replacement as per major society guidelines 14 Aneurysmectomy/ventricular reconstruction (IIbB) 2 Heart transplant or mechanical destination therapy
Chronic heart failure with preserved ejection fraction (HFPEF) (Fig. 1B) at the cost of promoting pulmonary oedema.
Ventricular hypertrophy and ischaemia also slow myocardial relaxation. Prolonged isovolumetric relaxation and delayed mitral valve opening, plus reduced ventricular compliance, mean that ventricular filling depends on adequate diastolic duration and atrial contraction. Hence, both tachycardia and atrial fibrillation exacerbate diastolic dysfunction.
Patients with diastolic failure may present with signs and symptoms of heart failure but >50% ejection fraction (EF ¼ [EDVÀ ESV]/EDV) on echocardiography, termed HF with preserved ejection fraction (HFPEF).
The hypertrophied LV is vulnerable to subendocardial ischaemia, readily provoked by tachycardia or increased afterload.
Diastolic function is evaluated by echocardiography (Table 1) . LAP is estimated by Doppler echocardiography or pulmonary artery wedge pressure (PAWP) using the pulmonary artery catheter (PAC); PAWP >16 mm Hg indicates severe HF.
2 Plasma B-type natriuretic peptide (BNP) is secreted constitutively from ventricular cardiomyocytes in response to pressure and volume overload; both BNP and PAWP can be monitored to track severity of left atrial hypertension and response to therapy. Occasionally, ADHF manifests tissue hypoperfusion without pulmonary oedema; judicious fluid loading to LAP that is above normal but does not precipitate pulmonary oedema is needed to recruit sufficient preload to restore/improve CO.
Afterload
LaPlace's law offers a rational definition of afterload as myocardial systolic wall stress S (N/m 2 ):
P V , the pressure that must be generated to eject blood, is determined by arterial impedance (a measure of how much the arterial circulation opposes the pulsatile flow of blood), which increases with arterial pressure and resistance. Hence, afterload is increased by conditions in which blood pressure and vascular tone are elevated (Table 1) . Similarly, conditions that acutely elevate R V , such as acute valvular incompetence, stress cardiomyopathy or ischaemia are associated with increased afterload.
ADHF frequently presents with hypertension: dyspnoea and low CO drive a catecholamine surge, whilst reduced forward flow increases filling pressures and EDV. The consequent increase in afterload exacerbates ADHF. Firstly, afterload closely correlates with myocardial metabolic demand; either increased P V or EDV can induce myocardial ischaemia. Secondly, Fig. 1C shows the deleterious effect of increasing arterial impedance on SV. During the ejection phase, the loop intersects the end-systolic ventricular elastance line (maximum pressure generated at a given ventricular volume, a measure of contractility) at a larger end-systolic volume, meaning that the aortic/pulmonary valve closes after ejection of a smaller SV.
The thin-walled RV (low W V ) is particularly susceptible to increases in pulmonary arterial impedance (e.g. hypoxic pulmonary vasoconstriction, pulmonary embolism).
Although wall stress is not usually calculated at the bedside, the main contributors to afterload-arterial blood pressure and ventricular size-can be measured and optimized: (Normal LV diameter-Female 2.4-3.2 cm/m 2 , Male 3.2-3.4 cm/m 2 ).
Contractility
Contractility defines the heart's ability to eject volume at prevailing afterload and preload. Pathology that diminishes contractility (Table 1 ) reduces the velocity of myocardial contraction and the maximal systolic ventricular pressure attained ( Fig. 1D ), attenuating the SV ejected before the aortic/pulmonary valve closes. Contractility is quantified experimentally by the endsystolic pressure-volume relationship 4 (red line in Fig. 1 ) but is challenging to measure clinically. Qualitative abnormalities of myocardial contractility are identified echocardiographically, including regional wall motion abnormalities associated with coronary artery lesions. Echocardiographic parameters such as myocardial shortening velocity, EF, and tricuspid annular plane systolic excursion (TAPSE-a measure of RV contraction) depend on preload and afterload and therefore do not accurately quantify contractility in isolation. However, when loading conditions are normal, derangement of these measurements may usefully identify impaired contractility.
Heart rate
Bradycardia reduces CO, which can directly precipitate ADHF; in addition, the accumulation of upstream venous pressure increases EDV, adding to afterload and potentially exacerbating mitral regurgitation as a consequence of annular stretch. Conversely, tachycardia increases myocardial oxygen demand and curtails coronary perfusion (which occurs predominantly during diastole); in case of coronary artery disease, demand may outstrip supply, exacerbating cardiac failure. Furthermore, in the case of mitral stenosis or impaired ventricular relaxation, tachycardia abbreviates diastole and may attenuate diastolic filling.
Pathophysiology of cardiogenic pulmonary oedema
Acutely reduced forward flow and subsequent neurohumoral activation augment LAP; pulmonary capillary engorgement promotes alveolar haemorrhage and oedema. Pulmonary oedema and response to therapy are typically identified (although poorly quantified) by chest X-ray. Lung ultrasound provides sensitive point-ofcare assessment of pulmonary oedema and quantification of effusions. Transpulmonary thermodilution to monitor extravascular lung water shows promise but is not yet recommended.
Adaptive and maladaptive responses to reduced cardiac output
Immediate haemodynamic consequences of diminished CO
The acutely failing ventricle (e.g. myocardial infarction) is distended by accumulating upstream blood volume that recruits preload reserve, restoring SV at the expense of increased ventricular radius (hence afterload) and LAP.
Neurohumoral adaptations
ADHF is associated with reduced CO: initially, reduced arterial pressure decreases the firing frequency of afferent nerves from the carotid sinus and aortic arch (CN IX and X, respectively), which disinhibits nuclei of the medullary cardiovascular centre. Sympathetic efferents project directly to the myocardium and vasculature, where noradrenaline release augments HR, contractility and vascular tone. Efferents projecting to the adrenal medulla stimulate adrenaline release with similar effect. Pulmonary congestion further augments sympathetic outflow as hypoxia and hypercarbia activate chemoreceptors, whilst dyspnoea drives central sympathetic activation. b 1 -Adrenergic activity and renal hypoperfusion also stimulate renin release, activating the rennin-angiotensin-aldosterone system (RAAS); unloading arterial baroreceptors stimulates vasopressin release through connections between the medullary cardiovascular centre and hypothalamus. Catecholamines restore CO by augmenting contractility and HR; mean arterial pressure (MAP) is also increased by catecholamines, angiotensin II and vasopressin-mediated vasoconstriction. Unfortunately, the neurohumoral response can be injurious: increasing HR, contractility, and afterload intensify myocardial oxygen demand; venoconstriction and RAASmediated renal sodium and water retention promote pulmonary oedema; and catecholamines can provoke arrhythmia, particularly in ischaemic myocardium. Noradrenaline, angiotensin II, vasopressin, and aldosterone augment CO at the expense of increased myocardial oxygen demand, afterload, and venous congestion. These reflexes evolved to drive a healthy heart to support blood pressure during exertion, haemorrhage, or dehydration; they are less suited to the modern clinical challenge of supporting the failing heart.
Managing cardiac failure
ADHF presents with life-threatening pulmonary oedema, low CO and tissue hypoperfusion, or both. Although immediate treatment priorities are to improve dyspnoea and support CO, survival depends on concurrent recognition and management of underlying precipitants 5 ( Table 1) . Therapies directed at respiratory support and optimizing preload, afterload and contractility in patients with ADHF are discussed below and in Table 2 .
A history of chest pain or drug ingestion, or examination findings of atrial fibrillation or hypothyroid features provide clues to underlying aetiology. Repeated admissions with HF, dyspnoea/fatigue when walking on flat ground or escalating diuretic requirements suggest severely impaired cardiac performance. 2 Electrocardiogram to identify ischaemia and arrhythmia, chest X-ray to identify pulmonary oedema or causes of cor pulmonale, and echocardiogram are essential. 2, 6 Besides identifying causes of ADHF and distinguishing HFPEF from HFREF, echocardiography provides global assessment of ventricular function, most commonly LVEF or SV (calculated using LV outflow Doppler). Notably, in the presence of aortic and mitral regurgitation EF is misleading because not all ejected blood contributes meaningfully to forward flow. RV EF is harder to measure; indices such as TAPSE and RV systolic velocity complement subjective RV assessment. Severe LV systolic dysfunction is usually defined by EF 30%; 2 EF predicts outcome in chronic HF, but prognostic value in ADHF is unknown. Routine PAC insertion is not recommended 2, 6 and its limitations must be appreciated; for example, PAWP predicts fluid responsiveness poorly and CO directed therapy has not demonstrably improved outcomes. Nevertheless, the PAC is useful in complex or refractory ADHF because CO, vascular resistance, pulmonary haemodynamics, and venous oxygenation (Grade IC) 2 can be monitored to assess the impact of inotropes, vasoactive therapy, and ventilation strategy. Transpulmonary CO monitors (e.g. thermal or lithium indicator) avoid risks of catheterizing the right heart and pulmonary artery whilst accurately measuring CO and its response to therapy. However, transpulmonary techniques do not directly monitor the pulmonary circulation.
Intravenous vasodilators, vasopressors and inotropes, and positive pressure ventilation should be administered in an appropriately equipped coronary or intensive care environment, 6 ideally with continuous intra-arterial pressure monitoring. Monitoring renal function, body weight, and fluid balance are mandatory.
ADHF often occurs as a deterioration of pre-existing HF; when tolerated, guideline-based goal-directed medical therapy should be continued or introduced (IB).
1,2,5,6
Respiratory support ADHF frequently presents with respiratory failure. Evidencebased oxygenation targets are lacking; most guidelines suggest maintaining arterial oxygen saturation >90%-possibly higher in cases of ischaemia. 2 An upper limit is rarely discussed, but clinicians should note that administering oxygen to nonhypoxic patients with cardiac disease induces coronary vasoconstriction, reducing coronary blood flow up to 30%; in animals, hyperoxia is consistently associated with impaired ventricular performance. High FiO 2 also exerts detrimental pulmonary effects. Cardiogenic pulmonary oedema is associated with hypoxia and increased elastic workload. Continuous positive airway pressure (CPAP) recruits alveoli and promotes propitious redistribution of extravascular lung water, reducing intrapulmonary shunt and work of breathing. Non-invasive ventilation decreases intubation rates and improves respiratory parameters, particularly in patients with hypercarbia. 7 Nevertheless, evidence of survival benefit is lacking. The optimal level of CPAP remains unknown, but 10 cm H 2 O appears safe and effective in most instances. Bi-level non-invasive support further reduces inspiratory work but has not demonstrated additional benefit. Deteriorating respiratory function mandates intubation and invasive ventilation; peri-induction hypoxia, positive intrathoracic pressure, and loss of sympathetic outflow can trigger catastrophic cardiovascular collapse; vasoactive/inotropic drugs must be to hand. Positive airway pressure has direct cardiac effects: reducing ventricular afterload, improving vascular conductance by recruiting lung, and improving myocardial oxygen supply benefit cardiac performance. Conversely, elevated intrathoracic pressure can limit RV filling and escalate RV afterload (by compressing intra-alveolar capillaries). Cardiopulmonary interactions are complex, unpredictable, and potentially deleterious; ventilation must be undertaken in a monitored, appropriately staffed environment.
Haemodynamic optimization: preload
The ideal LAP delivers enough preload (EDV) to ensure adequate SV without promoting upstream congestion. ADHF with pulmonary oedema indicates excessive LAP. Relieving LAP alleviates pulmonary congestion and, by countering excessive EDV, limits ventricular wall stress and functional mitral incompetence. Relieving LAP is contingent on venomotor relaxation, reducing circulating volume, and improving forward flow. 3 Early administration of i.v. loop diuretics and nitrates rapidly and effectively relaxes venomotor tone, relieving LAP; morphine has venodilator properties and also directly relieves breathlessness but can depress respiratory function. Continuous furosemide infusion seems physiologically rational, although superiority over bolus regimes is unproven. Continued diuretic use in the presence of uraemia is often associated with Heart failure Achieving optimal filling, striking the balance between augmenting tissue perfusion and precipitating pulmonary oedema, is challenging. Relieving pulmonary congestion by diuresis and venodilation can lead to inadequate preload, precipitating organ hypoperfusion, renal insufficiency, and counterproductive neurohumoral activation, particularly in the presence of diastolic dysfunction. Avoiding ischaemia, tachycardia, and atrial fibrillation are crucial to maximize LV filling without escalating LAP. When ADHF occurs without pulmonary oedema, CO may improve with fluid administration. Static indices-central venous pressure (CVP) and PAWP-do not accurately predict fluid responsiveness. Instead, the CO response to fluid bolus or passive leg raise should be directly monitored by echocardiography, PAC, or transpulmonary indicator whilst observing for respiratory deterioration.
Post-stabilization
Mineralocorticoid-receptor antagonists have diverse effects, besides diuresis, that improve outcomes in HF. 8 Chronic therapy
should continue unless contra-indicated and de novo therapy offered once renal dysfunction and hyperkalaemia resolve.
1,2,5
Afterload reduction
Higher afterload diminishes SV both directly and by placing metabolic demand on the myocardium. Moreover, even 'normal' afterload may compromise performance of the failing ventricle. Both arterial blood pressure and ventricular radius contribute to afterload. Timely blood pressure control is essential both to balance oxygen supply and demand and to restore SV (Fig. 1) . Guidelines suggest an initial systolic pressure target <110 mm Hg, 1 MAP should subsequently be titrated to ensure adequate tissue perfusion. Excessive EDV can be addressed by diuresis and venodilation, improving forward flow with inotropes, or by reducing arterial impedance. The latter is particularly important in case of valvular incompetence; promoting forward over retrograde flow. Despite being hypertensive, patients with ADHF are often relatively hypovolaemic as fluid is driven from engorged capillaries. As initial treatment relieves sympathetic drive, patients may become profoundly hypotensive, particularly after diuretic therapy. Accordingly, short-acting agents such as intravenous nitrates are used to control blood pressure acutely. Many traditional 'inotropes' are also vasodilators eliciting useful afterload reduction.
Intra-aortic balloon counterpulsation reduces afterload by synchronizing deflation with native systolic ejection, supporting CO when ADHF manifests with circulatory shock. By simultaneously augmenting diastolic coronary perfusion and reducing afterload, the IABP improves the balance between myocardial oxygen supply and demand.
The impaired RV is susceptible to increased afterload. Pulmonary arterial pressure monitoring may guide treatment, which includes: reversing hypoxia, acidosis, and hypercarbia; a ventilation strategy that minimizes atelectasis and alveolar overdistension; inhaled pulmonary vasodilators such as nitric oxide (inhaled therapies favour ventilation-perfusion matching and minimize systemic hypotension); and i.v. pulmonary vasodilators (e.g. milrinone).
Vasopressors (e.g. noradrenaline) increase afterload and therefore have a limited role in managing ADHF; they are reserved for patients who, despite adequate filling and inotropic support, cannot maintain MAP sufficient to appropriately distribute blood to vital organs. 5 Post-stabilization Angiotensin converting enzyme inhibitors (ACEi)/angiotensinreceptor blockers have benefits in HF extending beyond afterload reduction. 9 Therapy should continue in ADHF where pos- -channels, protecting against ischaemia-reperfusion injury. However, levosimendan is costly and difficult to titrate. Inotropes have important side-effects requiring appropriate monitoring. For example, adrenaline directly promotes lactic acid production, which although not injurious in itself, may be mistaken for, or obscure, lactic acidosis caused by tissue ischaemia. Despite improving hemodynamic status, inotropic agents have not demonstrated improved outcomes in ADHF. 2 In the absence of hypotension and shock, inotropes are not recommended (IIIC) 1 and have been associated with worse outcomes compared with placebo. 10 IABP may augment contractility by augmenting perfusion of ischaemic myocardium.
Post-stabilization b-Blockers depress CO and are contra-indicated in ADHF with tissue hypoperfusion or bradyarrhythmia (HR < 50 beats/min; 2 /3 AV block), in which context b-agonists are appropriate.
However, b-blockers improve survival in HFREF (favourably modulating myocardial energetics, electrical activity, geometry, adreno-receptor profiles, inflammation, and RAAS activity) and can safely continue in most patients with ADHF 11 or be introduced once ADHF resolves. 1, 2 In stable HF, b-blockers and vasodilators (e.g. ACEi), minimize myocardial workload. In cardiogenic shock, the clinician must balance the benefit vasopressors and inotropes bring in mitigating organ hypoperfusion against the additional cardiac work they impose.
Implantable electrical devices
In patients with pacemakers in situ (e.g. epicardial wires postcardiac surgery), rate titration (ideally maintaining AV Heart failure synchrony, e.g. AAI/DDD mode) can augment CO provided diastolic filling is preserved and excessive myocardial work avoided. Cardiac resynchronization therapy (CRT) increases SV by improving intra-and interventricular synchrony. Evidence has mostly accrued in patients with chronic HF; 12 nevertheless, in ADHF early CRT can facilitate weaning from inotropic/mechanical support.
Post-stabilization
Consider cardioverter-defibrillator in symptomatic HF with prior myocardial infarction and EF <35%.
2

Mechanical support
Intra-aortic balloon counterpulsation offers short-term support in ADHF where recovery is expected. Veno-arterial extracorporeal membrane oxygenation and ventricular assist devices (VADs) offer more durable, effective but invasive bridging to recovery, decision, or transplant.
Transplantation
Cardiac transplant improves quality of life and survival in selected patients with progressive, irreversible ADHF.
1,2
Conclusion
Understanding ADHF requires appreciation of how HR, preload, afterload, and contractility modulate cardiac performance. Therapeutic strategy is guided by underlying physiology.
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